Patricia A Ganz1, Carolyn C Gotay. 1. University of California, Los Angeles Schools of Medicine and Public Health, Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-6900, USA. pganz@ucla.edu
Abstract
PURPOSE: This article examines the challenges, opportunities, and successes that have occurred in the incorporation of patient-reported outcomes (PROs) in phase III cancer clinical trials. METHODS: An informal survey of the leadership of US cooperative group PRO investigators identified diverse trials in which PROs had been measured. Exemplary trials were selected for lessons learned and for examination of successful strategies. RESULTS: We review four challenging trials in depth, illustrating some of the difficulties in integrating PROs within treatment trials, including issues related to missing data, lack of procedures for monitoring patients and ensuring collection of PRO data, and missed opportunities in publication of treatment and PRO outcomes together. Four examples of successful trials are highlighted. CONCLUSION: As a result of this review, the authors make specific recommendations related to the use of PROs in phase III trials, focusing on issues related to design, choice of PRO instrument and frequency of administration, analysis, and publication strategies.
PURPOSE: This article examines the challenges, opportunities, and successes that have occurred in the incorporation of patient-reported outcomes (PROs) in phase III cancer clinical trials. METHODS: An informal survey of the leadership of US cooperative group PRO investigators identified diverse trials in which PROs had been measured. Exemplary trials were selected for lessons learned and for examination of successful strategies. RESULTS: We review four challenging trials in depth, illustrating some of the difficulties in integrating PROs within treatment trials, including issues related to missing data, lack of procedures for monitoring patients and ensuring collection of PRO data, and missed opportunities in publication of treatment and PRO outcomes together. Four examples of successful trials are highlighted. CONCLUSION: As a result of this review, the authors make specific recommendations related to the use of PROs in phase III trials, focusing on issues related to design, choice of PRO instrument and frequency of administration, analysis, and publication strategies.
Authors: Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag Journal: J Natl Cancer Inst Date: 2014-09-29 Impact factor: 13.506
Authors: Roxanne E Jensen; Arnold L Potosky; Carol M Moinpour; Tania Lobo; David Cella; Elizabeth A Hahn; David Thissen; Ashley Wilder Smith; Jaeil Ahn; George Luta; Bryce B Reeve Journal: J Clin Oncol Date: 2017-04-20 Impact factor: 44.544
Authors: Beate Mayrbäurl; Johannes M Giesinger; Sonja Burgstaller; Gudrun Piringer; Bernhard Holzner; Josef Thaler Journal: Support Care Cancer Date: 2015-07-01 Impact factor: 3.603
Authors: Vanessa L Beesley; Alexandra M Clavarino; Penelope M Webb; David K Wyld; Alessandra B Francesconi; Keith R Horwood; James D Doecke; Colleen A Loos; Adele C Green Journal: Support Care Cancer Date: 2009-09-24 Impact factor: 3.603
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Tito R Mendoza; Fengmin Zhao; Charles S Cleeland; Lynne I Wagner; Linda J Patrick-Miller; Michael J Fisch Journal: Clin Breast Cancer Date: 2013-06-28 Impact factor: 3.225
Authors: Ethan Basch; Amylou C Dueck; Lauren J Rogak; Lori M Minasian; William Kevin Kelly; Ann M O'Mara; Andrea M Denicoff; Drew Seisler; Pamela J Atherton; Electra Paskett; Lisa Carey; Maura Dickler; Rebecca S Heist; Andrew Himelstein; Hope S Rugo; William M Sikov; Mark A Socinski; Alan P Venook; Douglas J Weckstein; Diana E Lake; David D Biggs; Rachel A Freedman; Charles Kuzma; Jeffrey J Kirshner; Deborah Schrag Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 31.777